AUROPHARMA

Feb 13 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - FDA APPROVES ADQUEY FOR ATOPIC DERMATITIS

Source text: ID:nBSE9QTPmX

Further company coverage: ARBN.NS

(([email protected];))

** Shares of Aurobindo Pharma ARBN.NS fall around 8% to 1,106 rupees, its lowest since Oct. 31

** Stock set for its worst day since November 2022

** Pharma co posts 7.6% rise in Q3 profit to 9.1 billion rupees; consol rev rises 8.4% y/y

** Citi Research says Q3 beat was largely driven by favourable currency, continued strength in Europe

** Adds, co's flagship US generics business remains subdued

** More than 5.4 mln shares traded, 4.5x their 30-day avg

** YTD, ARBN down to ~6%

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Feb 9 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - COMPANY TO INVEST 660 MILLION RUPEES FOR 26% STAKE IN GARUDA RENEWABLES

• AUROBINDO PHARMA ONE-TIME CHARGE OF 653.3 MILLION RUPEES IN Q3 DUE TO NEW LABOUR CODES

Source text: ID:nBSE3X0Mpj

Further company coverage: ARBN.NS

(([email protected];;))

Feb 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTED UNIT-III OF EUGIA PHARMA

• AUROBINDO PHARMA - INSPECTION CONCLUDED WITH 11 PROCEDURAL OBSERVATIONS

Source text: ID:nNSE82jtld

Further company coverage: ARBN.NS

(([email protected];))

** Shares of India's Aurobindo Pharma ARBN.NS jump 4.28% to 1200.10 rupees

** Citi ("sell", PT: 1010 rupees) says India's minimum import price on penicillin-G removes uncertainty, lifting pricing visibility for domestic producers - note

** Brokerage adds the move could help improve utilisation at Aurobindo's penicillin-G plant which has been underutilized due to Chinese competition

** Trading volumes at 3.09 mln shares vs 30-day average of 800,425 shares

** Stock rated "buy" on avg by 25 analysts, median PT at 1337.50 rupees -- data compiled on LSEG

** ARBN dropped 11.35 in 2025, stock down ~2.7% in Jan

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

Jan 23 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - SUBSIDIARY INCORPORATED A NEW WHOLLY OWNED SUBSIDIARY IN PHILIPPINES

Source text: ID:nBSE4DzcXY

Further company coverage: ARBN.NS

(([email protected];))

** U.S. FDA approves application for generic version of GSK's Advair inhaler by partner of Aurobindo Pharma-owned ARBN.NS Lannett, Citi says

** Brokerage sees generic Advair adding $30 mln-$40 mln to co's annual U.S. revenues

** Notes additional competition from Aurobindo Pharma "marginal negative" for rival Cipla CIPL.NS, which expects FDA approval for gAdvair in near-term

** Adds Advair seen contributing $50 million to Cipla's U.S. revenue in FY27

** Aurobindo Pharma gets more than 50% of annual revenue from U.S.; Cipla earns ~29% from North America (mostly U.S.)

** Aurobindo Pharma said it would buy U.S.-based Lannett last year at enterprise value of $250 million

** ARBN down 0.6%; CIPL down 1.4%, second-biggest pct loser on Nifty 50 .NSEI

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Jan 9 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• CURATEQ RECEIVES NOC FROM CANADA HEALTH AUTHORITY FOR BIOSIMILAR DYRUPEG

Source text: ID:nNSE4n1MtQ

Further company coverage: ARBN.NS

(([email protected];))

Jan 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• TO BUY NON-ONCOLOGY PRESCRIPTION FORMULATIONS BUSINESS OF KHANDELWAL LABORATORIES

• CASH CONSIDERATION OF 3.25 BILLION RUPEES FOR ACQUISITION

Further company coverage: ARBN.NS

(([email protected];))

By Khushi Malhotra and Dharamraj Dhutia

MUMBAI, Oct 7 (Reuters) - India's Auro Realty, the real estate arm of Aurobindo Group which also owns drugmaker Aurobindo Pharma ARBN.NS, is planning to raise 20 billion rupees ($225.41 million) through the sale of bonds to fund a key acquisition, two merchant bankers said on Tuesday.

Auro Realty is looking to issue two-year and four-year bonds, with the coupons ranging from 11%-15%, the bankers added.

"It is a promoter-level financing to acquire some of the assets, including Hotel Taj Banjara Hyderabad," one of the bankers said.

The group did not reply to a Reuters email seeking comment, while the bankers requested anonymity as they are not authorised to speak to the media.

Auro Realty's bond issue is in advanced stages and could be completed as early as this month, while private credit funds are expected to be investors, the bankers added.

The bond issue adds to a rising trend of firms tapping the corporate bond market to fund large acquisitions.

($1 = 88.7275 Indian rupees)

(Reporting by Khushi Malhotra and Dharamraj Dhutia; Editing by Eileen Soreng)

(([email protected];))

Sept 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - SMALL FIRE INCIDENT OCCURRED IN GRANULATION AREA-10 OF UNIT IV OF APL HEALTHCARE

• AUROBINDO PHARMA LTD - 2 LINES IMPACTED FOR ABOUT TWO WEEKS

• AUROBINDO PHARMA LTD - NO CASUALTIES OR INJURIES REPORTED

• AUROBINDO PHARMA LTD - TEMPORARY PRODUCTION IMPACT ESTIMATED AT 3% OF CAPACITY

• AUROBINDO PHARMA LTD - REFURBISHMENT INITIATED, OPERATIONAL IN NEXT FEW WEEKS

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

Adds deal value from source in paragraph 2, background on Zentiva and previous deal reports from paragraph 4 onwards

Sept 11 (Reuters) - Czech generic drugmaker Zentiva 1SKF401E.BV said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value.

The deal values the Prague-based company at slightly more than 4 billion euros ($4.69 billion) including debt, according to a source with knowledge of the deal.

The Financial Times had first reported the deal on Wednesday, saying it was worth 4.1 billion euros.

Zentiva was acquired by Advent from French pharmaceutical giant Sanofi SASY.PA in 2018 for an enterprise value of 1.9 billion euros.

There have been reports of Advent mulling a sale of the generics drugmaker since 2021, with companies such as Polish drugmaker Polpharma and India's Aurobindo Pharma ARBN.NS reported to be joining the race.

Zentiva supplies a wide range of generic and over-the-counter drugs such as paracetamol and co-codamol to more than 100 million people across Europe.

($1 = 0.8530 euros)

(Reporting by Unnamalai L in Bengaluru and Andres Gonzalez Estebaran; Editing by Maju Samuel)

(([email protected];))

Sept 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - COMPLETION OF US FDA INSPECTION AT UNIT-XII OF AUROBINDO PHARMA

• AUROBINDO PHARMA - TOTAL OF 8 OBSERVATIONS ISSUED BY FDA

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];;))

This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here

By Nancy Lapid

Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.

Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.

“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.

Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.

Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.

The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.

“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.

Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.

RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS

Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.

In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.

The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.

A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.

There were no device malfunctions in either group.

The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.

“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.

“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.

Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.

(To receive the full newsletter in your inbox for free sign up here)

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

(([email protected]))

Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here

By Nancy Lapid

Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.

Clopidogrel tops aspirin for routine use in heart patients

The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.

Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.

“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.

Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.

Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.

The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.

“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.

Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.

Recycled pacemakers improve access in low-income nations

Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.

In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.

The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.

A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.

There were no device malfunctions in either group.

The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.

“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.

“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.

Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

(([email protected]))

Aug 26 (Reuters) - Aurobindo Pharma ARBN.NS:

• CURATEQ BIOLOGICS RECEIVES MHRA APPROVAL FOR DAZULBYS

Source text: ID:nNSE1Ys71d

Further company coverage: ARBN.NS

(([email protected];))

** Aurobindo Pharma ARBN.NS shares down 3.7 % at 1049.30 rupees, trimming earlier losses, after co says media reports on Zentiva deal "premature"

** Shares fell as much as 4.6% earlier in the session, their lowest since April 9, after reports said co was the front-runner to buy Prague-based Zentiva ROSCD.BX for $5.5 bln

** ARBN says no binding agreement or definitive decision has been made about the deal

** Around 3 mln shares traded, almost 2.7x their 30-day avg

** Twenty-six analysts covering ARBN have a "buy" rating on average; median PT is 1,300 rupees, per LSEG data

** As of Tuesday's close, stock is down ~20% YTD

(Reporting by Urvi Dugar)

(([email protected]))

** Shares of Aurobindo Pharma ARBN.NS fall as much as 2.7% to 1060.90 rupees

** Pharma co posts 10% y/y drop in June-qtr consol net PAT, expenses rise 5%

** ARBN rev rose 4% but missed analysts' expectations of Macquarie and Motilal Oswal

** Macquarie said revenue miss was driven by lower than expected revenue from the U.S. business

** Adds, muted growth in co's "bread and butter" U.S. business worrisome

** More than 2.5 mln shares traded, 2x their 30-day avg

** Stock last down 1%, taking YTD losses to 18%

(Reporting by Nishit Navin in Bengaluru)

(([email protected]))

Aug 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• Q1 CONSOL NET PROFIT 8.25 BILLION RUPEES

• Q1 CONSOL TOTAL REVENUE FROM OPERATIONS 78.68 BILLION RUPEES

• DIVIDEND 4 RUPEES PER SHARE

Further company coverage: ARBN.NS

(([email protected];;))

Aug 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - CLARIFIES REPORT TRUMP SHOOTS LETTERS TO GLOBAL DRUG MAJORS

• AUROBINDO PHARMA - NOT RECEIVED ANY COMMUNICATION AS PER MEDIA

Source text: ID:nBSEbwpshz

Further company coverage: ARBN.NS

(([email protected];))

July 30 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA LTD - TO BUY 100% INTEREST IN LANNETT SELLER HOLDCO

Source text: ID:nBSE8phxCw

Further company coverage: ARBN.NS

(([email protected];))

By Maggie Fick

LONDON, July 14 (Reuters) - ViiV Healthcare, the HIV-focused joint venture majority owned by GSK GSK.L, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting injectable HIV treatment cabotegravir.

The updated licence, which builds on an earlier agreement covering cabotegravir for HIV prevention, will enable three generic drugmakers to develop and supply the treatment for use in combination with Johnson & Johnson's JNJ.N rilpivirine in 133 countries, including all low-income, lower-middle income, and Sub-Saharan African nations.

ViiV's regimen -- the only approved long-acting injectable treatment for HIV -- is administered once every one or two months, an alternative to daily pills. The World Health Organization last week recommended long-acting cabotegravir and rilpivirine as a treatment option for people who are virologically suppressed but struggle with adherence to oral regimens.

The new licence also builds on an existing Medicines Patent Pool agreement covering cabotegravir for pre-exposure prophylaxis (PrEP), signed in 2022.

The existing licensees -- Aurobindo ARBN.NS, Cipla CIPL.NS and Viatris VTRS.O -- will now be able to develop and manufacture generic versions of the long-acting treatment, subject to regulatory approvals.

"As leaders in long-acting innovation we're proud to be expanding our voluntary licence to include treatment," said ViiV CEO Deborah Waterhouse. "We're committed to working with partners like MPP to increase access and reach those most impacted by HIV."

The announcement comes after Gilead Sciences GILD.O and the Global Fund to Fight AIDS, Tuberculosis and Malaria last week finalised a separate deal to supply long-acting HIV prevention drug, lenacapavir, to low-income countries at cost -- part of a push to expand access to innovative HIV medicines in the Global South.

ViiV is majority-owned by GSK, with Pfizer PFE.N and Shionogi 4507.T as shareholders.

(Reporting by Maggie Fick. Editing by Jane Merriman)

(([email protected]; +44 7890 916706;))

July 2 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - UNIT GETS MARKETING APPROVAL FOR TRASTUZUMAB BIOSIMILAR DAZUBLYS FROM EUROPEAN COMMISSION

Source text: ID:nnAZN430TLT

Further company coverage: ARBN.NS

(([email protected];;))

June 24 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - CURATEQ BIOLOGICS RECEIVES APPROVAL FOR BIOSIMILAR DYRUPEG FROM UK’S MHRA

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];;))

May 26 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - FIRST US FDA SUBMISSION PLANNED IN FY26

• AUROBINDO PHARMA - 8 BIOSIMILAR CANDIDATES WITH TAM OF GT50 BILLION USD IN 2030 UNDER DEVELOPMENT

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

Adds analyst comment in paragraph 6-7, updates shares

May 12 (Reuters) - Indian pharma stocks .NIPHARM fell 1.6% on Monday, bucking broader market gains, after U.S. President Trump said he would cut drug prices by 30%–80% to match other wealthy nations.

Trump said he would sign an executive order on Monday to pursue "most favored nation" pricing.

The U.S. currently pays nearly three times more for many prescription drugs, though Trump offered no implementation details. Several Indian drugmakers earn a significant share of their revenue from North America by selling low-cost generic versions of newer drugs.

Thirteen of 20 stocks on the pharma sub-index fell, led by Sun Pharma’s 4.6% drop, even as the Nifty 50 .NSEI gained 2.5%; Zydus Life ZYDU.NS and Cipla CIPL.NS also declined 0.7% each.

Divi's Laboratories DIVI.NS and Lupin LUPN.NS fell 2% each, while Biocon BION.NS lost nearly 3%.

"A price cut of prescription drugs by 50% or more would hurt the U.S. formulations market, more on the branded size due to immediate potential impact, while over the medium term it will also impact generics as it reduces the potential market size of new drugs," said Shrikant Akolkar, an analyst at Nuvama Institutional Equities.

"Indian branded players like Sun Pharma, Biocon and Zydus Life may see an impact upon strict implementation," Akolkar said.

The U.S. accounts for nearly a third of India's pharma exports, which rose 16% to about $9 billion last fiscal year, according to government-backed trade body Pharmexcil.

(Reporting by Kashish Tandon in Bengaluru; Editing by Nivedita Bhattacharjee and Mrigank Dhaniwala)

(([email protected]; 8800437922;))

** Shares of drug maker Aurobindo Pharma ARBN.NS rise as much as 4.2% to 1,237.70 rupees

** Unit receives U.S. FDA's approval for Dasatinib tablets

** Adds, Dasatinib, used as anti-cancer medication, is expected to be launched in Q1FY26

** Stock top gainer in Nifty Pharma Index .NIPHARM which is up 1.1%

** Share price above 50-day, 100-day and 200-day exponential moving averages

** Avg rating of 25 analysts equivalent of "buy", median PT is 1,463 rupees - data compiled by LSEG

** Stock last up 4.1%, cutting YTD loss to 7.3%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Aurobindo Pharma ARBN.NS rises 3.8% to 1123 rupees, their biggest one-day gain in over a month

** ARBN biggest gainer in the Nifty pharma index .NIPHARM, which is up 1.8%

** Drug maker gets U.S. FDA's final approval to manufacture and market Rivaroxaban Tablets USP, 2.5 mg

** Drug, which is used to treat blood clots, will be launched in Q1FY26

** Avg of analysts' rating on the stock is "Buy;" median PT is 1463 rupees - data compiled by LSEG

** Stock down 16% YTD vs 11% decline in the pharma index

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.

U.S. accounts for a third of India's overall pharma exports.

Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.

On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.

Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.

Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.

The pharma index has fallen 14.4% this year.

(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)

(([email protected];))